Name
Recognizing and Addressing Risks of Shifting Epidemiology of Pneumococcal Disease in Adults 50+
Speakers
Content Presented On Behalf Of:
Merck
Services/Agencies represented
Executive Advisory Board (EAB)
Session Type
Breakout
Date
Tuesday, March 3, 2026
Start Time
2:30 PM
End Time
3:30 PM
Location
National Harbor 6-7
Learning Outcomes
• Discuss the ongoing burden and shifting epidemiology of pneumococcal disease in adults 50+
• Review the robust clinical trial program to help address invasive pneumococcal disease and pneumococcal pneumonia
• Highlight CDC recommendations for adult pneumococcal disease, including lowering vaccination age from 65 to 50
• Review the robust clinical trial program to help address invasive pneumococcal disease and pneumococcal pneumonia
• Highlight CDC recommendations for adult pneumococcal disease, including lowering vaccination age from 65 to 50
CE/CME Session
Non-CE Session
Session Currently Live